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ARTICLE IN PRESSLetter to the EditorInterelukin-1 Receptor Antagonist in Animal Models of Stroke:
A Fair Summing Up?
To the Editor:
We read with interest Banwell et al’s systematic review and
stratified meta-analysis of the efficacy of interleukin-1
receptor antagonist (IL-1RA) in animal models of stroke re-
cently published in the Journal.1 IL-1RA fares quite well,
demonstrating a 38% reduction in infarct volume overall.
This compares favorably to the 24% reduction reported
in a meta-analysis of preclinical data for tissue plasmino-
gen activator.2 In contrast to other similar meta-analyses,3,4
in which the efficacy detected in individual studies
declined with higher ‘‘quality scores,’’ the reported
efficacy of IL-1RA increases when more of the 10 ‘‘quality
items’’ are reported in the study’s methods.
We welcome the authors’ thorough analysis of much of
the current knowledge regarding the efficacy of IL-1RA
in animal models of stroke, and agree that there is room
for improvements in the conduct of preclinical studies
in stroke. Meta-analysis is clearly a very powerful tool
in both preclinical and clinical studies; however, data
other than histological or functional outcome, such as
pharmacokinetics, should be considered as well.5
We feel that some aspects of the design and execution of this
meta-analysis may weaken the authors’ conclusion that
‘‘the animal data supporting IL-1RA as a candidate drug
for stroke are limited, and that further experiments are re-
quired before proceeding to clinical trial.’’ The factors cho-
sen for inclusion in the quality score are vital to conducting
high- quality preclinical stroke research, but nonetheless
we feel that some items, and their application, require fur-
ther study or refinement. First, the 10 quality score factors
are given equal weighting in the analysis, even though
some factors (eg, avoidance of anaesthetics with marked in-
trinsic neuroprotective properties, control of temperature)
will have a far greater potential to introduce error and
bias than others (eg, peer-reviewed publication, statement
of compliance with animal regulations). This issue was dis-
cussed in an earlier article cowritten by one of the authors in
2004,6 and we agree that a weighted score would be a useful
refinement. Second, studies in comorbid animals are in-
cluded in the quality score, but there is no evidence that
studying the effects of treatments in such animals is of
any more value than doing so in young, healthy animals,
a point also discussed in the original article describing
this methodology.6 There is little evidence of a penumbra1052-3057/$ - see front matter
 2010 by National Stroke Association
doi:10.1016/j.jstrokecerebrovasdis.2010.01.005in comorbid animals,7 even though one is frequently iden-
tified in stroke patients.8 Third, not making a statement re-
garding any potential conflict of interest scores ‘‘0,’’ but the
score given for a reported conflict of interest is not clear.
Given the binary nature of the scoring system, it could
only either have no impact on the quality score (relative
to not making a statement) or improve it. This also may
require some modification.
Despite the authors’ comprehensive search strategy and
hand-searching of conference abstracts, the quality score
for one study was taken from an abstract,9 even though
the full article has been available online since 2007.5 The
information required to calculate the quality score for
this study could not have been included in a short
abstract, and thus this study received a quality score of
1 out of 10, whereas we believe that the score would
have been 4 had it been based on the full publication.
This highlights the importance of distinguishing between
‘‘not done’’ and ‘‘not reported,’’ and the consequent
impact on the score. Although we certainly advocate the
reporting of all such factors in future studies, some of
the 10 quality items (eg, statement of compliance with
animal welfare regulations) have not previously been
routinely reported, but this does not equate to ‘‘not done.’’
The systematic review highlights the need to improve
experimental procedures and addresses the issue of
differences between preclinical and clinical studies. How-
ever, it seems appropriate to recognize the limitations of
the meta-analysis methodology, and it would be incorrect
to assume that this article is a definitive account of IL-1-
RA’s potential as a treatment for clinical stroke. The
blanket application of this methodology to potential
stroke treatments could even be potentially damaging to
the field of stroke research, and, as with the experimental
methodology that it addresses, further refinement is
probably needed to improve its value.
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